Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis
Utilizing JAK inhibitors such as upadacitinib in treating uveitis, whether in isolated forms or in the context of systemic autoimmune diseases, may require further evaluation by controlled cohort studies.
Authors
- D. Díaz Domínguez
- Matlock A. Jeffries (ORCID: https://orcid.org/0000-0001-9516-4312)
- Cynthia K. McClard (ORCID: https://orcid.org/0000-0003-3122-0623)
- Jila Noori
- Sawyer Vaclaw
Institutions
- Veterans Health Administration (US)
- Oklahoma State University Medical Center (US)
- Oklahoma Medical Research Foundation (US)
- Cincinnati Eye Institute (US)
- Dean McGee Eye Institute (US)
- University of Oklahoma Health Sciences Center (US)
- University of Oklahoma (US)
Publication Details
- Journal
- Journal of Ophthalmic and Vision Research
- Published
- 2025-05-05
- DOI
- https://doi.org/10.18502/jovr.v20.14952
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00